{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:07:02Z","timestamp":1792195622527,"version":"4.4.0"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00868","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:23:31Z","timestamp":1589847811000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":238,"title":["IL-15 in the Combination Immunotherapy of Cancer"],"prefix":"10.3389","volume":"11","author":[{"given":"Thomas A.","family":"Waldmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milos D.","family":"Miljkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"Conlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nri3191","article-title":"Adoptive immunotherapy for cancer: harnessing the T cell response","volume":"12","author":"Restifo","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e20191062","DOI":"10.1084\/jem.20191062","article-title":"IL-15 (dys) regulation of lymphoid homeostasis: implications for therapy of autoimmunity and cancer","volume":"217","author":"Waldmann","year":"2020","journal-title":"J Exp Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"4940","DOI":"10.1073\/pnas.91.11.4940","article-title":"The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells","volume":"91","author":"Bamford","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4935","DOI":"10.1073\/pnas.91.11.4935","article-title":"A lymphokine, provisionally designed interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells","volume":"91","author":"Burton","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"B6","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1126\/science.8178155","article-title":"Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor","volume":"264","author":"Grabstein","year":"1994","journal-title":"Science"},{"key":"B7","first-page":"213","article-title":"IL-15 cytokine","volume-title":"The Cytokine Reference. A Compendium of Cytokines and Other Mediators of Host Defense.","author":"Waldmann","year":"2000"},{"key":"B8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1182\/blood.V97.1.14","article-title":"Interleukin 15: biology and relevance to human disease","volume":"297","author":"Fehniger","year":"2001","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1002\/eji.200939444","article-title":"Homeostatic proliferation and survival of na\u00efve and memory T cells","volume":"39","author":"Boyman","year":"2009","journal-title":"Eur J Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nri1052","article-title":"Cytokine control of memory T-cell development and survival","volume":"3","author":"Schluns","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1038\/ni.2744","article-title":"The developmental pathway for CD103+CD8+ tissue-resident memory T cells of skin","volume":"14","author":"Mackay","year":"2013","journal-title":"Nat Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1038\/s41385-018-0016-5","article-title":"Human intraepithelial lymphocytes","volume":"11","author":"Mayassi","year":"2018","journal-title":"Mucosal Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.immuni.2014.08.003","article-title":"T-bet orchestrates CD8\u03b1\u03b1 IEL differentiation","volume":"41","author":"Kwong","year":"2014","journal-title":"Immunity"},{"key":"B14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.immuni.2014.06.018","article-title":"The transcription factor T-bet is induced by IL-15 and thymic agonist selection and controls CD8\u03b1\u03b1(+) intraepithelial lymphocyte development","volume":"41","author":"Klose","year":"2014","journal-title":"Immunity"},{"key":"B15","doi-asserted-by":"publisher","first-page":"14601","DOI":"10.1038\/ncomms14601","article-title":"IL-15 sustains IL-7R-independent ILC2 and ILC3 development","volume":"8","author":"Robinette","year":"2017","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.immuni.2013.02.010","article-title":"Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12-and IL-15 responsive IFN-\u03b3-producing cells","volume":"38","author":"Fuchs","year":"2013","journal-title":"Immunity"},{"key":"B17","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3389\/fimmu.2017.00438","article-title":"HiJAKing innate lymphoid cells?","volume":"8","author":"Sciume","year":"2017","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/jlb.59.4.476","article-title":"IL-15: the role of translational regulation in their expression","volume":"59","author":"Bamford","year":"1996","journal-title":"J Leukoc Biol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1073\/pnas.93.7.2897","article-title":"Interleukin (IL)-15\/IL-T production by the adult T-cell leukemia line HuT-102 is associated with a human T-cell lymphotrophic virus type 1 region\/IL-15 fusion message that lacks many upstream AUGs that normally attenuate IL-15 mRNA translation","volume":"93","author":"Bamford","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"B20","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nri1901","article-title":"The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design","volume":"6","author":"Waldmann","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1158\/1078-0432.CCR-12-3603","article-title":"Molecular pathways: interleukin-15 signaling in health and in cancer","volume":"20","author":"Mishra","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1172\/JCI119258","article-title":"A potential role for interleukin-15 in the regulation of human natural killer cell survival","volume":"99","author":"Carson","year":"1997","journal-title":"J Clin Invest"},{"key":"B23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0369-8114(03)00098-1","article-title":"Cytokine-driven proliferation and differentiation of human na\u00efve, central memory and effector memory CD4+ T cells","volume":"51","author":"Geginat","year":"2003","journal-title":"Pathol Biol (Paris)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.blre.2005.10.001","article-title":"Human natural killer cell development and biology","volume":"20","author":"Farag","year":"2006","journal-title":"Blood Rev"},{"key":"B25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/icb.2014.1","article-title":"The unconventional expression of IL-15 and its role in NK cell homeostasis","volume":"92","author":"Huntington","year":"2014","journal-title":"Immunol Cell Biol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"11445","DOI":"10.1073\/pnas.200363097","article-title":"IL-2 induced activation-induced cell death is inhibited in IL-15 transgenic mice","volume":"97","author":"Marks-Konczalik","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"B27","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S1074-7613(02)00429-6","article-title":"IL-15R alpha recycles and presents IL-15 in trans to neighboring cells","volume":"17","author":"Dubois","year":"2002","journal-title":"Immunity"},{"key":"B28","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1146\/annurev.immunol.24.021605.090727","article-title":"Diverse functions of IL-2, IL-15 and IL-7 in lymphoid homeostasis","volume":"24","author":"Ma","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1182\/blood-2003-12-4187","article-title":"Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance","volume":"105","author":"Kobayashi","year":"2005","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.immuni.2007.03.006","article-title":"Dendritic cells prime natural killer cells by trans-presenting interleukin 15","volume":"26","author":"Lucas","year":"2007","journal-title":"Immunity"},{"key":"B31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1084\/jem.20082013","article-title":"IL-15 trans-presentation promotes human NK cell development and differentiation in vivo","volume":"206","author":"Huntington","year":"2009","journal-title":"J Exp Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.cyto.2012.06.017","article-title":"Regulating the immune system via IL-15 transpresentation","volume":"59","author":"Castillo","year":"2012","journal-title":"Cytokine"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.celrep.2013.08.021","article-title":"IL-15 cis presentation is required for optimal NK cell activation in lipopolysaccharide-mediated inflammatory conditions","volume":"4","author":"Zanoni","year":"2013","journal-title":"Cell Rep"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-61737-979-6_1","article-title":"Regulatory T cells: history and perspective","volume":"707","author":"Sakaguchi","year":"2011","journal-title":"Methods Mol Biol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1146\/annurev.immunol.17.1.221","article-title":"Mature T lymphocyte apoptosis\u2014immune regulation in a dynamic and unpredictable antigenic environment","volume":"17","author":"Lenardo","year":"1999","journal-title":"Annu Rev Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1600-065X.2010.00917.x","article-title":"The power and the promise of restimulation-induced cell death in human immune diseases","volume":"236","author":"Snow","year":"2010","journal-title":"Immunol Rev"},{"key":"B37","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nm827","article-title":"Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15","volume":"9","author":"Brentjens","year":"2003","journal-title":"Nat Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1006\/cimm.1995.1216","article-title":"Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth-factor: comparison with interleukin-2","volume":"165","author":"Munger","year":"1995","journal-title":"Cell Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1073\/pnas.0307298101","article-title":"IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8(+) T cells","volume":"101","author":"Klebanoff","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"B40","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nm1359","article-title":"Interleukin-15 rescues tolerant CD8(+) T cells for use in adoptive immunotherapy of established tumors","volume":"12","author":"Teague","year":"2006","journal-title":"Nat Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"6845","DOI":"10.1182\/blood-2011-09-377804","article-title":"IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood","volume":"118","author":"Sneller","year":"2011","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.1182\/blood-2010-10-311456","article-title":"Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques","volume":"117","author":"Waldmann","year":"2011","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J. Clin. Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-17-2451","article-title":"A first-in-human phase I study of subcutaneous outpatient recombinant human IL15 (rhIL15) in adults with advanced solid tumors","volume":"24","author":"Miller","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"4945","DOI":"10.1158\/1078-0432.CCR-18-3468","article-title":"IL-15 by continuous intravenous infusion to adult patients with solid tumors in a Phase I trial induced dramatic NK-cell subset expansion","volume":"25","author":"Conlon","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1182\/blood-2017-12-823757","article-title":"First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation","volume":"131","author":"Romee","year":"2018","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","first-page":"5552","DOI":"10.1158\/1078-0432.ccr-18-0945","article-title":"Phase I trial of ALT-803, a novel recombinant IL-15 complex, in patients with advanced solid tumors","volume":"24","author":"Margolin","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1172\/jci.insight.96219","article-title":"Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect","volume":"3","author":"Felices","year":"2018","journal-title":"JCI Insight."},{"key":"B49","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1158\/2326-6066.CIR-17-0279","article-title":"IL15 infusion of cancer patients expands the subpopulation of cytotoxic CD56bright NK cells and increases NK-cell cytokine release capabilities","volume":"5","author":"Dubois","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"3598","DOI":"10.4049\/jimmunol.0901244","article-title":"Novel human interleukin-15 agonists","volume":"183","author":"Zhu","year":"2009","journal-title":"J Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"18093","DOI":"10.1074\/jbc.M113.461756","article-title":"Characterization and favorable in vivo properties of heterodimeric soluble IL-15-IL-15R\u03b1 cytokine compared to IL-15 monomer","volume":"288","author":"Chertova","year":"2013","journal-title":"J Biol Chem"},{"key":"B52","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1074\/jbc.M705725200","article-title":"Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity","volume":"283","author":"Bergamaschi","year":"2008","journal-title":"J Biol Chem"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1182\/blood-2011-10-384362","article-title":"Circulating IL-15 exists as heterodimeric complex with soluble IL-15R\u03b1 in human and mouse serum","volume":"120","author":"Bergamaschi","year":"2012","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.cyto.2018.01.011","article-title":"Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques","volume":"108","author":"Bergamaschi","year":"2018","journal-title":"Cytokine"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.4161\/mabs.28699","article-title":"Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse","volume":"6","author":"Vincent","year":"2014","journal-title":"MAbs"},{"key":"B56","doi-asserted-by":"publisher","first-page":"P347","DOI":"10.1186\/2051-1426-3-S2-P347","article-title":"Combination therapy of an IL-15 superagonist complex, ALT-803, and a tumor targeting monoclonal antibody promotes direct antitumor activity and protective vaccinal effect in a syngenic mouse melanoma model","volume":"3","author":"Chen","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B57","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12967-019-1778-6","article-title":"Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model","volume":"17","author":"Furuya","year":"2019","journal-title":"J Transl Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1038\/mt.2016.88","article-title":"Enhanced ADCC and NK cell activation of an anticarcinoma bispecific antibody by genetic insertion of a modified IL-15 cross-linker","volume":"24","author":"Schmohl","year":"2016","journal-title":"Mol Ther"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1074\/jbc.M508624200","article-title":"Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta\/gamma. Hyperagonist IL-15 X IL-15R alpha fusion proteins","volume":"281","author":"Mortier","year":"2006","journal-title":"J Biol Chem"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1158\/1535-7163.MCT-09-0275","article-title":"High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer","volume":"8","author":"Bessard","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"B61","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/ijc.28059","article-title":"Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency","volume":"133","author":"Vincent","year":"2013","journal-title":"Int J Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"E10915","DOI":"10.1073\/pnas.1811615115","article-title":"IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages","volume":"115","author":"Zhang","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B63","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10549-011-1360-2","article-title":"IL-15 and IL-2 increase cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR","volume":"130","author":"Roberti","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"B64","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1158\/1078-0432.CCR-15-1419","article-title":"The IL-15-based ALT-803 complex enhances Fc gamma RIII\u03b1-triggered NK cell responses and in vivo clearance of B cell lymphomas","volume":"22","author":"Rosario","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.exphem.2011.08.006","article-title":"Interleukin-15 enhances rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells and overcomes transforming growth factor beta-mediated immunosuppression","volume":"39","author":"Moga","year":"2011","journal-title":"Exp Hematol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"23869","DOI":"10.1074\/jbc.M116.733600","article-title":"A novel fusion of ALT-803 (interleukin (IL)-15 superagonist) with an antibody demonstrates antigen-specific antitumor responses","volume":"291","author":"Liu","year":"2016","journal-title":"J Biol Chem"},{"key":"B67","doi-asserted-by":"publisher","first-page":"7513","DOI":"10.1073\/pnas.0902637106","article-title":"Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer","volume":"106","author":"Zhang","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"B68","doi-asserted-by":"publisher","first-page":"6156","DOI":"10.4049\/jimmunol.1102604","article-title":"Augmented IL-15R\u03b1 expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice","volume":"188","author":"Zhang","year":"2012","journal-title":"J Immunol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"6187","DOI":"10.1073\/pnas.1203479109","article-title":"Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model","volume":"109","author":"Yu","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B70","doi-asserted-by":"publisher","first-page":"6019","DOI":"10.1158\/1078-0432.CCR-10-1966","article-title":"Simultaneous blockage of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model","volume":"16","author":"Yu","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"10867","DOI":"10.1016\/j.biopha.2019.108677","article-title":"Development of a recombinant human IL-15. SIL-15R\u03b1\/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model","volume":"112","author":"Zhao","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.ymthe.2018.07.013","article-title":"Superagonist IL-15-armed oncolytic virus elicits potent antitumor immunity and therapy that are enhanced with PD-1 blockade","volume":"26","author":"Kowalsky","year":"2018","journal-title":"Mol Ther"},{"key":"B73","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40425-019-0551-y","article-title":"Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy","volume":"7","author":"Knudson","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B74","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","article-title":"ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial","volume":"19","author":"Wrangle","year":"2018","journal-title":"Lancet Oncol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1182\/bloodadvances.2018028332","article-title":"First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia","volume":"3","author":"Cooley","year":"2019","journal-title":"Blood Adv"},{"key":"B76","article-title":"Interleukin-15 (IL-15) and alemtuzumab for relapsed\/refractory mature T-cell malignancies [abstract]","volume-title":"Proceedings of the 2020 T-cell Lymphoma Forum","author":"Miljkovic","year":"2018"},{"key":"B77","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/ni.3470","article-title":"CIS is a potent checkpoint in NK cell-mediated tumor immunity","volume":"17","author":"Delconte","year":"2016","journal-title":"Nat Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"S875","DOI":"10.21037\/tcr.2016.10.79","article-title":"CIS is a negative regulator of IL-15-mediated signals in NK cells","volume":"5","author":"Bottino","year":"2016","journal-title":"Transl Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.immuni.2015.06.023","article-title":"Out-of-sequence signal 3 paralyzes primary CD4(+) T-cell-dependent immunity","volume":"43","author":"Sckisel","year":"2015","journal-title":"Immunity"},{"key":"B80","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/30996","article-title":"Help for cytotoxic-T-cell responses is mediated by CD40 signalling","volume":"393","author":"Bennett","year":"1998","journal-title":"Nature"},{"key":"B81","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/30989","article-title":"A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell","volume":"393","author":"Ridge","year":"1998","journal-title":"Nature"},{"key":"B82","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/31002","article-title":"T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions","volume":"393","author":"Schoenberger","year":"1998","journal-title":"Nature"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1126\/science.1206954","article-title":"Inhibitory Fc\u03b3 receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies","volume":"333","author":"Li","year":"2011","journal-title":"Science"},{"key":"B84","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.ccell.2016.05.001","article-title":"Therapeutic activity of agonistic, human anti-CD40 monoclonal antibodies requires selective Fc\u03b3R engagement","volume":"29","author":"Dahan","year":"2016","journal-title":"Cancer Cell"},{"key":"B85","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.4049\/jimmunol.1102609","article-title":"Antigen-independent induction of Tim-3 expression on human T cells by the common \u03b3-chain cytokines IL-2, IL-7, IL-15 and IL-21 is associated with proliferation and is dependent on the phosphoinositide 3-kinase pathway","volume":"188","author":"Mujib","year":"2012","journal-title":"J Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"e1005349","DOI":"10.1371\/journal.ppat.1005349","article-title":"TIGIT marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV infection","volume":"12","author":"Chew","year":"2016","journal-title":"PLoS Pathog"},{"key":"B87","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1093\/intimm\/dxn052","article-title":"CD8+CD122+ regulatory T cells recognize activated T cells via conventional MHC class I-alphabeta TCR interaction and become IL-10-producing active regulatory cells","volume":"20","author":"Rifa'i","year":"2008","journal-title":"Int Immunol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"168","DOI":"10.4049\/jimmunol.1600019","article-title":"IL-15 trans-signaling with the superagonist RL1 promotes effector\/memory CD8+ T cell responses and enhances antitumor activity of PD-1 antagonists","volume":"197","author":"Desbois","year":"2016","journal-title":"J Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00868\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:23:35Z","timestamp":1589847815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00868\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,19]]},"references-count":88,"alternative-id":["10.3389\/fimmu.2020.00868"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00868","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,19]]},"article-number":"868"}}